SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Apple Turns 50: From Garage Startup to AI Crossroads 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
 to Present at the 9th Annual Biotech Showcase in San Francisco - EconoTimes)
SHANGHAI, China and CUPERTINO, Calif., Jan. 04, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Company has been selected to present at the 9th Annual Biotech Showcase to be held from January 9-11, 2017 in San Francisco, CA. The Company will present an update on its operations, activities and clinical research progress.
| Conference: | 9th Annual BioTech Showcase 2017 | ||
| Date: | Tuesday, January 10, 2017 | ||
| Time: | 10:30 AM PST | ||
| Presenter: | Tony (Bizuo) Liu, Chief Executive Officer | ||
| Location: | Room 2 (Ballroom Level) Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA | ||
| Live webcast: | https://event.webcasts.com/viewer/event.jsp?ei=1130607 | ||
Company management will attend the conference and be available for discussions. To arrange one-to-one meetings with management, please contact [email protected]. The presented material will be available on the Company website following the presentations.
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 408-973-7884 [email protected] Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 [email protected]
